Protect your patients’ path toward remission

The National Cancer Comprehensive Network® (NCCN) recommendation for G-CSF use during chemotherapy

Returning to the clinic to receive UDENYCA® may increase patient comfort.2

See patient survey results

UDENYCA® delivers the reliable outcomes you expect, but with 35% cost savings per dose vs Neulasta®.*5

Discover the value of UDENYCA®

UDENYCA® was confirmed to be highly similar to Neulasta®, with no clinically meaningful differences.2-4

View proven biosimilarity

* Based on wholesale acquisition cost (WAC). WAC does not necessarily reflect actual prices paid by consumers, pharmacies, or third-party payers. UDENYCA® WAC of $4175 per prefilled syringe vs Neulasta® WAC of $6417 per prefilled syringe.

References: 1. Kuderer, M. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia. J Clin Oncol. 2007; 25(21):1-10 2. Data on file. Coherus BioSciences, Inc.; 2021. 3. UDENYCA® (pegfilgrastim-cbqv) package insert. Redwood City, CA: Coherus BioSciences, Inc.; 2021. 4. Neulasta® (pegfilgrastim) package insert. Thousand Oaks, CA: Amgen Inc.; 2021. 5. Data on file. Coherus BioSciences, Inc.; 2022.